JPS5557521A - Medicine for allergy - Google Patents
Medicine for allergyInfo
- Publication number
- JPS5557521A JPS5557521A JP13863079A JP13863079A JPS5557521A JP S5557521 A JPS5557521 A JP S5557521A JP 13863079 A JP13863079 A JP 13863079A JP 13863079 A JP13863079 A JP 13863079A JP S5557521 A JPS5557521 A JP S5557521A
- Authority
- JP
- Japan
- Prior art keywords
- allergy
- medicine
- agent
- prophylaxis
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19782846412 DE2846412A1 (de) | 1978-10-25 | 1978-10-25 | Mittel zur behandlung allergischer reaktionen |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5557521A true JPS5557521A (en) | 1980-04-28 |
JPS645009B2 JPS645009B2 (ja) | 1989-01-27 |
Family
ID=6053066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13863079A Granted JPS5557521A (en) | 1978-10-25 | 1979-10-25 | Medicine for allergy |
Country Status (6)
Country | Link |
---|---|
US (1) | US4344938A (ja) |
EP (1) | EP0010309B2 (ja) |
JP (1) | JPS5557521A (ja) |
AT (1) | ATE1443T1 (ja) |
CA (1) | CA1148081A (ja) |
DE (2) | DE2846412A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61155335A (ja) * | 1984-12-28 | 1986-07-15 | Green Cross Corp:The | 免疫調節剤 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2853453A1 (de) * | 1978-12-11 | 1980-06-19 | Behringwerke Ag | Mittel zur therapie von immunkomplexerkrankungen |
US4517181A (en) * | 1982-09-15 | 1985-05-14 | The Salk Institute For Biological Studies | Mammalian PGRF |
AT383739B (de) * | 1983-03-16 | 1987-08-10 | Immuno Ag | Verfahren zur inaktivierung von unvertraeglichkeitsreaktionen verursachenden substanzen in immunglobulinhaeltigen blutfraktionen |
AT383737B (de) * | 1983-03-16 | 1987-08-10 | Immuno Ag | Verfahren zur verwendung einer immunoglobulin-g enthaltenden fraktion |
FR2556219B1 (fr) * | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
US5026545A (en) * | 1984-09-17 | 1991-06-25 | Baxter International, Inc. | Treatment of allergy and composition therefor |
US4740371A (en) * | 1984-09-17 | 1988-04-26 | International Institute Of Cellular And Molecular Pathology | Treatment of allergy |
US5543145A (en) * | 1984-09-17 | 1996-08-06 | Baxter International, Inc. | Pharmaceutical composition and method for the suppression of factor VIII inhibitor production |
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US5422258A (en) * | 1987-12-31 | 1995-06-06 | Tanox Biosystems, Inc. | Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils |
GB8824869D0 (en) * | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
US5681566A (en) * | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
CA2015515C (en) | 1990-01-03 | 1999-12-07 | Jean-Marie Saint-Remy | Pharmaceutical compositions containing antigen-antibody complexes and uses therefor |
CZ96893A3 (en) * | 1990-11-23 | 1993-12-15 | Gen Hospital Corp | Inhibition of adhesive protein cells and their carbohydrates interaction |
US7794970B2 (en) * | 2005-09-20 | 2010-09-14 | Amgen Inc. | Method for generating F(ab′)2 antibody fragments |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2123198A (en) * | 1936-10-23 | 1938-07-12 | Lederle Lab Inc | Treatment of antitoxins and the like |
DE1148037B (de) * | 1961-10-11 | 1963-05-02 | Behringwerke Ag | Verfahren zur Herstellung eines desaggregierten, das Komplementsystem nicht beeinflussenden Gammaglobulins |
CH392780A (de) * | 1961-12-07 | 1965-05-31 | Schweiz Rotes Kreuz | Verfahren zur Herstellung von intravenös anwendbaren Antikörperpräparaten humanen Ursprungs |
FR1459501A (fr) * | 1965-12-03 | 1966-11-18 | Procédé d'élimination de la cytotoxicité d'un sérum thérapeutique | |
FR2222083B1 (ja) * | 1973-03-22 | 1976-05-14 | Fontaine Michel | |
DE2414219A1 (de) * | 1973-03-26 | 1974-10-10 | Parke Davis & Co | Mittel zur immunoregulation von pollenallergie |
DE2602443A1 (de) * | 1975-04-04 | 1976-10-21 | Univ California | Biologisch aktive polypeptide |
US4190646A (en) * | 1975-11-11 | 1980-02-26 | Sloan-Kettering Institute For Cancer Research | Polypeptide compositions and methods |
DE2610854A1 (de) * | 1976-03-15 | 1977-09-22 | Biotest Serum Institut Gmbh | Galenische immunglobulinzubereitung |
US4164495A (en) * | 1976-04-06 | 1979-08-14 | Nordisk Insulinlaboratorium | Method of recovering immunoglobulin using a polyol and an alkanoic acid |
SE436645C (sv) * | 1976-04-29 | 1996-07-22 | Bonnierfoeretagen Ab | Antigeniskt aktiv polypeptid, som kan användas vid cancerdiagnosticering och vid framställning av antikroppar |
US4075193A (en) * | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
US4190647A (en) * | 1979-01-26 | 1980-02-26 | Sloan-Kettering Institute For Cancer Research | Polypeptides and methods |
JPS55124719A (en) * | 1979-03-22 | 1980-09-26 | Kowa Co | Preparation of immune globulin administrable by intravenous injection |
-
1978
- 1978-10-25 DE DE19782846412 patent/DE2846412A1/de active Granted
-
1979
- 1979-10-19 AT AT79104054T patent/ATE1443T1/de not_active IP Right Cessation
- 1979-10-19 EP EP79104054A patent/EP0010309B2/de not_active Expired
- 1979-10-19 DE DE7979104054T patent/DE2963550D1/de not_active Expired
- 1979-10-23 US US06/087,481 patent/US4344938A/en not_active Expired - Lifetime
- 1979-10-24 CA CA000338305A patent/CA1148081A/en not_active Expired
- 1979-10-25 JP JP13863079A patent/JPS5557521A/ja active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61155335A (ja) * | 1984-12-28 | 1986-07-15 | Green Cross Corp:The | 免疫調節剤 |
Also Published As
Publication number | Publication date |
---|---|
EP0010309B1 (de) | 1982-08-11 |
JPS645009B2 (ja) | 1989-01-27 |
EP0010309A3 (en) | 1980-06-25 |
US4344938A (en) | 1982-08-17 |
EP0010309A2 (de) | 1980-04-30 |
CA1148081A (en) | 1983-06-14 |
DE2846412C2 (ja) | 1989-01-12 |
ATE1443T1 (de) | 1982-08-15 |
EP0010309B2 (de) | 1989-01-25 |
DE2963550D1 (en) | 1982-10-07 |
DE2846412A1 (de) | 1980-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5557521A (en) | Medicine for allergy | |
NL7900871A (nl) | Werkwijze voor de therapeutische behandeling van hyperlipidemie en hyperlipiproteinemie. | |
NO884795D0 (no) | Rekombinant, humant immunoglobulin og fremgangsmaate for fremstilling av dette. | |
NO158741C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive kvartaere dibenzotiepin-n-alkyl-norskopinetere. | |
NO883540D0 (no) | Fremgangsmaate og anlegg for behandling av slam. | |
GB2100601B (en) | An aromatase-inhibitor for use in a method of prophylaxis and/or of treatment by therapy of prostatic hyperplasia, and pharmaceutical preparations suitable for such a use. | |
NO873699D0 (no) | Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser. | |
GR3005768T3 (ja) | ||
ATE101648T1 (de) | Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors. | |
GB8423081D0 (en) | Benzothiophene derivatives | |
GR3029774T3 (en) | Method of preparing a radioactive rhenium complex solution. | |
DK462583A (da) | Insekticidt produkt og fremgangsmaade til fremstilling deraf | |
DE69133068D1 (de) | Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen | |
DE3474672D1 (en) | Alkylated fab or fc fragments of human igg, process for their preparation and pharmaceutical compositions | |
DE3381624D1 (de) | Mittel zur behandlung von wunden. | |
FI853389A0 (fi) | Tumoerlaekemedel och foerfarande foer dess framstaellning. | |
ATE2049T1 (de) | Mittel zur therapie von immunkomplexerkrankungen. | |
MX9301858A (es) | Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv. | |
IS2589A7 (is) | Aðferð til framleiðslu efnis til meðferðar á auknum hárvexti og til varnar flösu. | |
HUT36783A (en) | Process for preparing 1,7-diphenyl-3-methyl-aza-7-cyano-8-methyl-nonane | |
NO883603D0 (no) | Humane monoklonale antistoffer og profylaktiske og terapeutiske midler mot infektioese sykdommer inneholdende disse som effektiv bestanddel. | |
IE811612L (en) | Thiazoles | |
SE8306384D0 (sv) | Farmaceutisk komposition | |
NO841466L (no) | Neutron-kilde av akseleratortypen og fremgangsmaate for styring av denne. | |
ATE17190T1 (de) | Mittel zur tumorlokalisierung und therapie mit markierten antikoerpern und antikoerperfragmenten. |